
Illumina (ILMN) Stock Forecast & Price Target
Illumina (ILMN) Analyst Ratings
Bulls say
Illumina is well-positioned to capture a share of this growing market. Additionally, the company's strong financial position, with over $3.7 billion in cash and short-term investments, provides a cushion against any potential challenges. Based on Illumina's strong clinical adoption and potential for future growth in this area, I have a positive outlook on the company's stock.
Bears say
Illumina is facing multiple challenges in terms of growth sustainability in the clinical consumables market, as they are already experiencing high growth but still need to meet investor expectations while facing competition from other companies. Furthermore, their long-term growth projections are based on pre-China and pre-Aca/Gov changes, and there are potential risks such as academic demand remaining weak and sales declining in China. Additionally, there is strong competition in the nextgen sequencing market and sustainability issues such as environmental footprint and human capital management that the company must address.
This aggregate rating is based on analysts' research of Illumina and is not a guaranteed prediction by Public.com or investment advice.
Illumina (ILMN) Analyst Forecast & Price Prediction
Start investing in Illumina (ILMN)
Order type
Buy in
Order amount
Est. shares
0 shares